CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
CytomX Therapeutics (CTMX) Tops Q2 EPS by 17c
August 8, 2023 4:29 PM EDTCytomX Therapeutics (NASDAQ: CTMX) reported Q2 EPS of ($0.02), $0.17 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $24.7 million versus the consensus estimate of $13.68 million.
For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.
... More